| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Katrine B Hansen, Tina Vilsbøll, Filip K Kno. Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 3. 2011-07-14. PMID:21437085. |
they bind to and activate glucagon-like peptide-1 (glp-1) receptors on pancreatic beta-cells following which insulin secretion and synthesis are initiated. |
2011-07-14 |
2023-08-12 |
Not clear |
| Stanley Schwartz, Benjamin A Koh. Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 3. 2011-07-14. PMID:21437091. |
advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with glp-1 receptor agonists, weight maintenance with dpp-iv inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on cv function. |
2011-07-14 |
2023-08-12 |
Not clear |
| Sung Hoon Yu, Bongjun Cho, Yejin Lee, Eunhye Kim, Sung Hee Choi, Soo Lim, Ka Hee Yi, Young Joo Park, Kyong Soo Park, Hak Chul Jan. Insulin secretion and incretin hormone concentration in women with previous gestational diabetes mellitus. Diabetes & metabolism journal. vol 35. issue 1. 2011-07-14. PMID:21537414. |
we examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) on insulin secretion in women with previous gestational diabetes (pgdm). |
2011-07-14 |
2023-08-12 |
Not clear |
| Mala Dharmalingam, Usha Sriram, Manash P Barua. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian journal of endocrinology and metabolism. vol 15. issue 1. 2011-07-14. PMID:21584160. |
glucagon like peptide-1 (glp-1) is an incretin hormone secreted from the small intestine that lowers fasting and postprandial glucose through multiple mechanisms including glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying and increased satiety. |
2011-07-14 |
2023-08-12 |
human |
| Shi-Ying Ding, Andongfac Nkobena, Catherine A Kraft, Michele L Markwardt, Megan A Rizz. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells. The Journal of biological chemistry. vol 286. issue 19. 2011-07-12. PMID:21454584. |
glucagon-like peptide 1 (glp-1) potentiates glucose-stimulated insulin secretion from pancreatic β cells, yet does not directly stimulate secretion. |
2011-07-12 |
2023-08-12 |
mouse |
| Shi-Ying Ding, Andongfac Nkobena, Catherine A Kraft, Michele L Markwardt, Megan A Rizz. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells. The Journal of biological chemistry. vol 286. issue 19. 2011-07-12. PMID:21454584. |
co-expression of wt or mutant gck proteins with a sensor for insulin secretory granule fusion also revealed that blockade of post-translational gck s-nitrosylation diminished the effects of glp-1 on granule exocytosis by ∼40% in βtc3 cells. |
2011-07-12 |
2023-08-12 |
mouse |
| Ryuzo Kawamor. [The concept of incretins and the physiological roles of incretins]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595259. |
incretins, exemplified by glucagon-like peptide 1(glp-1) and glucose-dependent insulinotropic polypeptide (gip) are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion. |
2011-07-08 |
2023-08-12 |
Not clear |
| Hisamitsu Ishihar. [Cross-talk among pancreatic alpha, beta and delta cells stimulated by incretin hormones]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595261. |
incretin hormones, glp-1 and gip, contribute to whole body glucose homeostasis by modulating secretion of islet hormones, insulin, glucagon and somatostatin. |
2011-07-08 |
2023-08-12 |
Not clear |
| Hisamitsu Ishihar. [Cross-talk among pancreatic alpha, beta and delta cells stimulated by incretin hormones]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595261. |
both glp-1 and gip stimulate insulin and somatostatin secretion. |
2011-07-08 |
2023-08-12 |
Not clear |
| Tadao Shibasaki, Susumu Sein. [Regulatory mechanism of incretin secretion]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595262. |
incretin hormones gip(glucose-dependent insulinotropic polypeptide) and glp-1 (glucagon-like peptide-1) improve glycemic control by potentiating glucose-induced insulin secretion in pancreatic beta-cells and also have beneficial effects on appetite control and body weight. |
2011-07-08 |
2023-08-12 |
Not clear |
| Yukihiro Fujita, Masakazu Haned. [Molecular mechanism of insulin secretion facilitated by incretin]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595263. |
incretins, such as gip and glp-1 enhance insulin secretion from pancreatic beta cells in a glucose dependent manner. |
2011-07-08 |
2023-08-12 |
Not clear |
| Norio Harad. [Structure and function of incretin receptor]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595264. |
gip and glp-1 have not only pancreatic effect, such as potentiation of insulin secretion but also many extrapancreatic effects. |
2011-07-08 |
2023-08-12 |
human |
| Masafumi Ono, Keisuke Oe, Toshiji Saibar. [Attenuation of fatty accumulation in hepatocyte by incretin--expectation of novel medicine for treatment of NASH]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595271. |
glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide(gip) function as incretin and stimulate glucose-mediated insulin production by pancreatic beta cells. |
2011-07-08 |
2023-08-12 |
Not clear |
| Masamitsu Nakazat. [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595282. |
glp-1(7-36)nh2 is a major molecular form that stimulates insulin release, reduces food intake, and has a potential to promote beta-cell regeneration. |
2011-07-08 |
2023-08-12 |
Not clear |
| Masamitsu Nakazat. [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595282. |
intranasal administration of glp-1 increased its plasma level, stimulated postprandial insulin release, and suppressed glucagon release. |
2011-07-08 |
2023-08-12 |
Not clear |
| Jun-Ichiro Miyagawa, Masayuki Miuchi, Mitsuyoshi Namb. [Incretin-based therapy in patients with type 1 diabetes mellitus]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595283. |
glp-1 has multiple physiological functions including glucose-dependent insulin secretion and glucagon suppression, delay of gastic emptying, suppression of hepatic glucose production, stimulation of beta cell replication and neogenesis, inhibition of beta cell apoptosis. |
2011-07-08 |
2023-08-12 |
Not clear |
| Mayumi Enya, Yukio Horikawa, Jun Taked. [Association between polymorphisms of TCF7L2 and type 2 diabetes with special reference to incretin action]. Nihon rinsho. Japanese journal of clinical medicine. vol 69. issue 5. 2011-07-08. PMID:21595284. |
although the mechanisms by which tcf7l2 affects susceptibility to type 2 diabetes remain to be elucidated, several studies have shown that decreased tcf7l2 protein inhibits the insulin secretory response to oral glucose through impaired incretin action(glp-1, gip). |
2011-07-08 |
2023-08-12 |
Not clear |
| T Thatava, T J Nelson, R Edukulla, T Sakuma, S Ohmine, J M Tonne, S Yamada, Y Kudva, A Terzic, Y Iked. Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene therapy. vol 18. issue 3. 2011-07-06. PMID:21048796. |
further guidance, under insulin-like growth factor 1 (igf-1), hepatocyte growth factor (hgf) and n-[n-(3,5-difluorophenacetyl)-l-alanyl]-s-phenylglycine t-butyl ester (dapt), was enhanced by glucagon-like peptide-1 (glp-1) to generate islet-like cells that expressed pancreas-specific markers including insulin and glucagon. |
2011-07-06 |
2023-08-12 |
human |
| Michael A Nauck, Juris J Meie. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nature reviews. Endocrinology. vol 7. issue 4. 2011-07-05. PMID:21326278. |
pharmacotherapy: glp-1 analogues and insulin: sound the wedding bells? |
2011-07-05 |
2023-08-12 |
Not clear |
| Hui Min Chan, Ritesh Jain, Bo Ahrén, Giovanni Pacini, David Z D'Argeni. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 5. 2011-06-30. PMID:21307364. |
the increase in insulin secretion caused by glucagon-like peptide-1 (glp-1) and glp-1 mimetics observed during an intravenous glucose test (ivgtt) has been reported in both normal and disease animal models, as well as in humans. |
2011-06-30 |
2023-08-12 |
mouse |